Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.
Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?
The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.
Leqembi is an FDA-Approved Alzheimer’s treatment. Hospital infusions take an hour each. 2025 is looking to see a new 15-second autoinjector version. For some, it should even work at home.
Why are some of the new anti-Alzheimer’s antibodies better than others? With the FDA’s approval of Lecanemab and Donanemab, it’s worth staying on top of this topic’s latest research.
The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.
Right now, there are two FDA approved drugs to treat Alzheimer’s itself. Find out why Remternetug may soon get approval as a third, even better treatment.
Kisunla, the newest Alzheimer’s drug, is rapidly gaining acceptance around the world. Learn what it does and how to get it.
How do the new drugs Leqembi and Kisunla fight Alzheimer’s? Surprisingly, increases in amyloid-beta protein levels can explain the slowing of Alzheimer’s at least as well as the reduction in amyloid plaques.
Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.
You cannot control the wind, But you can adjust your sails.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?
STRESS affects Alzheimer’s risk. Find out how. Learn 10 ways to de-stress and relax.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
